We are live on
!
Find out more
EC
Elmind Capital Portfolio holdings
AUM
$352M
This Fund
S&P 500
This Quarter
Est. Return
+51.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$339M
AUM Growth
–
Cap. Flow
+$288M
Cap. Flow
% of AUM
85.07%
Top 10 Holdings %
Top 10 Hldgs %
68.55%
Holding
34
New
34
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Cogent Biosciences
COGT
|
+$32.9M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$32.4M |
| 3 |
Viridian Therapeutics
VRDN
|
+$23.5M |
| 4 |
Celldex Therapeutics
CLDX
|
+$22.8M |
| 5 |
CG Oncology
CGON
|
+$20.4M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
UroGen Pharma
URGN
$1.92B
| $2.34M | 0.69% |
+100,000
| New | +$2.17M |
|
27
Immunocore
IMCR
$1.65B
| $2.02M | 0.6% |
+58,248
| New | +$2.06M |
|
28
Design Therapeutics
DSGN
$865M
| $1.95M | 0.58% |
+207,900
| New | +$1.63M |
|
29
enGene Therapeutics
ENGN
$125M
| $1.9M | 0.56% |
+210,000
| New | +$1.68M |
|
30
Alector
ALEC
$168M
| $1.4M | 0.41% |
+900,000
| New | +$1.6M |
|
31
Amylyx Pharmaceuticals
AMLX
$1.94B
| $1.35M | 0.4% |
+112,000
| New | +$1.52M |
|
|
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
| $1.26M | 0.37% |
+50,000
| New | +$1.17M |
|
33
Supernus Pharmaceuticals
SUPN
$2.75B
| $994K | 0.29% |
+20,000
| New | +$972K |
|
34
Edgewise Therapeutics
EWTX
$4.44B
| $744K | 0.22% |
+30,000
| New | +$602K |
|
Similar funds
PIC
MCMU
SC
FWM
BMWM
ACA
BFS
BL